[ADOC regimen for unresectable advanced thymic cancer].

Abstract

Between 1996 and 1998, we treated 6 patients with unresectable and advanced thymic cancer (stages IVa and IVb). All received 50 mg/m2 of cisplatin and 40 mg/m2 of doxorubicin intravenously (i.v.) on day 1,0.6 mg/m2 of vincristine i.v. on day 3, and 700 mg/m2 of cyclophosphamide i.v. on day 4; ADOC regimen, respectively at 3-4 week intervals. Four patients obtained a partial response (PR) after ADOC chemotherapy and the overall clinical response rate was 67%. No life-threatening side effects were noted. In 2 patients, cisplatin plus VP-16 chemotherapy failed to demonstrate any benefits prior to the ADOC regimen. Radiotherapy was initiated after the achievement of PR in the other 2 patients. ADOC chemotherapy appears to be an effective treatment for thymic cancer.

• Authors: T Koizumi, Y Takabayashi, S Yamagishi, K Tsushima, A Takamizawa, S Takashi, A Tsukadaira, T Masubuchi, H Yamamoto, T Kaneki, S Yamaguchi, T Hachiya, M Hayasaka, K Fujimoto, K Kubo
• Journal: Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society (Nihon Kokyuki Gakkai Zasshi) Vol. 37 Issue 12 Pg. 970-3 (Dec 1999) ISSN: 1343-3490 [Print] Japan
• PMID: 10707536 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Squamous Cell (therapy)
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Radiotherapy, Adjuvant
• Thymus Neoplasms (therapy)
• Treatment Outcome
• Vincristine (administration & dosage)